nab-Paclitaxel for treatment of solid tumors: Beyond breast cancer

Community Oncology

Volumn 5, Issue 6 SUPPL. 7, 2008, Pages 8-15

  Rosenberg, Larry J ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CASTOR OIL; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; DRUG SOLVENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; HYDROXYUREA; INTERLEUKIN 2; LACTATE DEHYDROGENASE; NANOPARTICLE; NAVELBINE; OSTEONECTIN; PACLITAXEL; PLATINUM; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; VASCULOTROPIN;

ADD ON THERAPY; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG UPTAKE; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SENSORY NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 46049109098     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Friedrich M, Diesing D, Villena-Heinsen C, Felberbaum R, Kolberg HC, Diedrich K. Taxanes in the first-line chemotherapy of metastatic breast cancer: review. Eur J Gynaecol Oncol 2004;25:66-70.
2. Ramalingam S, Belani CP. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother 2002;3:1693-1709.
3. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005;50:355-374.
4. Wiernik PH, Einzig AI. Taxol in malignant melanoma. J Natl Cancer Inst Monogr 1993;15:185-187.
5. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455-464.
6. Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 2000;27(suppl 7):3-7.
7. du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol 1999;10(suppl 1):35-41.
8. Taxol (paclitaxel) injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2003.
9. Taxotere (docetaxel) injection concentrate [package insert]. Bridgewater, NJ: Aventis Pharmaceutical Products, Inc; April 2003.
10. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-1642.
11. rd, Diéras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 2003;89(suppl 3):S16-S22.
12. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000;23:401-428.
13. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-1268.
14. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-1598.
15. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-685.
16. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-1457.
17. van Tellingen O, Huizing MT, Panday VR, et al. Cremophor EL causes (pseudo-) nonlinear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999;81:330-335.
18. Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007;13:345-357.
19. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremophor-EL-free formulation of paclitaxel. Nanomed 2007;2:415-423.
20. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999;30:339-344.
21. Sakai N, Baba M, Nagasima Y, et al. SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol 2001;32:1064-1070.
22. Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-5380.
23. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007;7:919-943.
24. Rugo HS. Taxane alternatives: efficacy and toxicity. Commun Oncol 2008;5(suppl 3):10-16.
25. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-6026.
26. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
27. Gradishar W, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25(18S):1032.
28. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
29. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
30. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
31. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997;108:210-214.
32. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002;25:283-286.
33. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006;106:375-382.
34. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-7793.
35. Hersh EM, O'Day S, Gonzalez R, Samlowski WE, Gordon MS, Hawkins MJ. Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma. J Clin Oncol 2005;23(16S):7558.
36. Ramalingam S. First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel. Clin Lung Cancer 2005;7(suppl 3):S77-S82.
37. Milton DT, Miller VA. Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer. Semin Oncol 2005;32:299-314.
38. Gebbia V, Oniga F, Agueli R, Paccagnella A. Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin? Ann Oncol 2006;17(suppl 2):ii83-ii87.
39. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004;9(suppl 2):16-23.
40. Suzuki M, Hao C, Takahashi T, et al. Aberrant methylation of SPARC in human lung cancers. Br J Cancer 2005;92:942-948.
41. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263-1268.
42. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008;26:639-643.
43. James LP, Kris MG, Heelan RT, et al. A phase II study to determine if sensory neuropathy of nab-paclitaxel can be reduced by prolonging infusion in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25 (18S):18087.
44. Bonomi P. Review of paclitaxel/carboplatin in advanced non-small cell lung cancer. Semin Oncol 1999;26(suppl 2):55-59.
45. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane), on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007;60:759-766.
46. Hawkins MJ, Manikhas G, Makhson A, et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18S):7659.
47. Allerton JP, Hagenstad CT, Webb RT, et al. A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(18S):7127.
48. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-2939.
49. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
50. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007;25(18S):LBA7514.
51. Reynolds C, Barrera D, Vu DQ, et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18S):7610.
52. Thomas H, Rosenberg P. Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit Rev Oncol Hematol 2002;44(suppl):S43-S51.
53. rd. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J Clin Oncol 2003;21(suppl):133s-135s.
54. Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 2000;78(pt 1):336-341.
55. Teneriello MG, Tseng PC, Crozier M, et al. Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2007;25(18S):5525.
56. rd. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006;100:437-438.